Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“There is increasing evidence suggesting that the pathogenesis of Alzheimer’s disease is not restricted to amyloid-b plaques and tau tangles but also includes strong interactions with immunological mechanisms.(1) In line with this, astrocyte reactivity or astrocytosis is a well-known pathological process that is common…”
BackgroundMethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Items 501–600 of 660
Cardiovascular rate pressure product is associated with NfL in older adults at risk for AD
Odo, C. C., Strong, J., Lose, S. R., Ma, Y., Gallagher, C. L., Bendlin, B. B., Zetterberg, H., Blennow, K., Carlsson, C. M., Kollmorgen, G., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70086
Self-citationZhang, M., Sun, C.-K., Chen, Y., Hao, Q., Zhang, Z., Guo, F., Tan, L., & Tan, M. (2024) · ASEAN Journal of Psychiatry · doi:10.54615/2231-7805.144469
Biomarkers as Outcome Measures in Clinical Trials of Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_15
PAPEL DA NEUROINFLAMAÇÃO NA PATOGÊNESE DA DOENÇA DE ALZHEIMER
DIAS, I. O., Queiroz, M. S. O., Borlini, V. M., & Lamim, L. D. S. C. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-257-4.20
Bergoc, G. G. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2022.tde-22072025-152610
Posttraumatic Stress Disorder (PTSD) and Glial Suppression
Kritikos, M., & Clouston, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_144
GSDME unlocks astrocyte-driven neurotoxicity in Alzheimer’s DiseasePreprint
Xie, X., Ji, C., Xu, J., Lu, X., Guo, G., Wu, X., Liu, W., Chen, Y., Zhang, Y., Wang, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672784
Changes in Plasma Aβ42/40 Ratio and p-Tau181 in Amyloid-Positive Patients Treated with Sirolimus
Leibowitz, J., Kumi, F., Naseif, A., Leibowitz, E. J., & Baumeister, C. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00323-1
Sex specific differences of protein expression profiles in Alzheimer’s disease
Tian, F., Zhang, Y., Li, J., Meng, S., Ge, W., & Wang, X. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb-2025-5121
Integrated multi-omics analysis identifies potential therapeutic targets for Alzheimer’s disease
Li, H., Kang, J., Liang, Z., Wang, X., Zhu, L., Tang, H., & Peng, W. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00493
Tamura, R., Taguchi, R., Yamada, T., Wada, H., Ayaki, T., Takahashi, R., & Urushitani, M. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578779
Acosta, G. T., Yang, S., Calvo-Marín, J., Moghekar, A., Kamalian, A., & Lutz, M. W. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.10.004
Gao, S., Gross, A. L., Aksman, L., Anwar, M., Crimmins, E. M., Dey, S., Gupta, A., Thyagarajan, B., Lee, J., & Nichols, E. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251393588
Upadhyay, K. D., Viramgami, A., Singh, D., Kulkarni, N., Chudasama, B., Sivaperumal, P., & Balachandar, R. (2025) · Research Square · doi:10.21203/rs.3.rs-7788186/v1
Pelkmans, W., Cacciaglia, R., Kassinopoulos, M., Grau‐Rivera, O., Minguillón, C., Molinuevo, J. L., Kollmorgen, G., Quijano‐Rubio, C., Wilson, R. E., Jonaitis, E. M., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00987-5
Self-citationBun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614732
Lin, J., Ou, R., Li, C., Hou, Y., Zhang, L., Wei, Q., Pang, D., Kun⁃cheng, L., Jiang, Q., Yang, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24515967
Lohman, T., Kapoor, A., Engstrom, A. C., Shenasa, F., Alitin, J. P. M., Gaubert, A., Rodgers, K. E., Bradford, D. R., Mather, M., Han, S. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26731345
Wang, X., Shi, Z., Qiu, Y., Sun, D., & Zhou, H. (2024) · Figshare · doi:10.6084/m9.figshare.26719356
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614744
Vrillon, A., Bousiges, O., Götze, K., Demuynck, C., Muller, C., Ravier, A., Schorr, B., Philippi, N., Hourrègue, C., Cognat, E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26170575
Chiotis, K., Johansson, C., Rodriguez‐Vieitez, E., Ashton, N. J., Blennow, K., Zetterberg, H., Graff, C., & Nordberg, A. K. (2024) · Figshare · doi:10.6084/m9.figshare.26615596
Self-citationAdditional file 1 of The dynamics of plasma biomarkers across the Alzheimer’s continuum
Guo, Y., Shen, X.-N., Wang, H.-F., Chen, S.-D., Zhang, Y.-R., Chen, S., Cui, M., Cheng, W., Dong, Q., Ma, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26567207
Wang, X., Zhang, X., Liu, J., Zhang, J., Liu, C., Cui, Y., Song, Q., Hou, Y., Wang, Y., Zhang, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25599864
Liu, T., Zuo, H., Ma, D., Song, D., Zhao, Y., & 承欧梅 (2023) · Figshare · doi:10.6084/m9.figshare.23722198
Guo, T., Li, A., Sun, P., He, Z., Cai, Y., Lan, G., Liu, L., Li, J., Yang, J., Zhu, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26410059
Lorenzini, L., Zanella, L., Sannia, M., Baldassarro, V. A., Moretti, M., Cescatti, M., Quadalti, C., Baldi, S., Bartolucci, G., Gloria, L. D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26723867
Altomare, D., Libri, I., Alberici, A., Rivolta, J., Padovani, A., Ashton, N. J., Zetterberg, H., Blennow, K., & Borroni, B. (2024) · Figshare · doi:10.6084/m9.figshare.25802834
Self-citationBiofluid and neurophysiological biomarkers in amyotrophic lateral sclerosis
Vacchiano, V. (2024) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.48676/unibo/amsdottorato/11249
Targeting the M1 muscarinic acetylcholine receptor in neurodegeneration
Hesse, S. (2023) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.83466
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614741
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614735
Guo, T., Li, A., Sun, P., He, Z., Cai, Y., Lan, G., Liu, L., Li, J., Yang, J., Zhu, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26409831
Svenningsson, A. L., Stomrud, E., Palmqvist, S., Hansson, O., & Ossenkoppele, R. (2022) · Figshare · doi:10.6084/m9.figshare.21269527
Self-citationYang, Z., Sreenivasan, K. R., Toledano Strom, E. N., Osse, A. M. L., Pasia, G., Cosme, C. G., Mugosa, M. R. N., Chevalier, E. L., Ritter, A., Miller, J. B., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24499375
Yang, Z., Sreenivasan, K. R., Toledano Strom, E. N., Osse, A. M. L., Pasia, G., Cosme, C. G., Mugosa, M. R. N., Chevalier, E. L., Ritter, A., Miller, J. B., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24499431
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614738
Understanding astrocyte-derived extracellular vesicles in health and disease
White, K. (2024) · Nottingham ePrints (University of Nottingham)
Pait, M. C. (2023) · WakeSpace Scholarship (Wake Forest University)
Beyond amyloid: contributions of cerebrovascular injury to Alzheimer’s disease
Rizvi, B. (2024) · eScholarship (California Digital Library)
Ettinger, S., Jeindl, R., & Erdös, J. (2023) · Repository of the Ludwig Boltzmann Institute of Health Technology Assessment (Ludwig Boltzmann Institute of Health Technology Assessment)
Epigenetics in neurodegeneration: Emerging biomarkers and translational insights
Singh, H., Gurjar, S., & Taliyan, R. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150005
Quack, C. M. H. (2025) · Gutenberg Open Science · doi:10.25358/openscience-13716
Is there a link between multiple sclerosis and Alzheimer disease? A critical note
Jellinger, K. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03073-0
Rodríguez‐Fernández, B., Escalante, A. G., Genius, P., Evans, T. E., Ortiz‐Romero, P., Minguillón, C., Kollmorgen, G., Ashton, N. J., Zetterberg, H., Blennow, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz70856_098828
Self-citationHam, H. J., Park, S. S., Lee, Y. S., Kim, T. H., Son, D. J., Kim, J.-H., Lim, K., Park, H., Lee, H. J., Yun, J., et al. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1728279
Biomarcadores de neuroinflamação em pacientes com COVID-19 e doenças neurológicas
Passos, F. R. S. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Huang, Z., Liu, W., Zhang, Y., Zha, B., Wang, P., & Yang, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1708008
The Dementia Cascade: From the Preclinical Stage
Chen, Q., Xu, J., Gao, H., & Cai, H. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_1
Proteins as Candidates for the Neurodegeneration Biomarkers
Бокша, И. С., Prokhorova, T. A., Savushkina, O. K., Терешкина, Е. Б., Vorobyeva, E. A., & Burbaeva, G. S. (2025) · Neurochemical Journal · doi:10.1134/s1819712425700631
An integrated CSF-serum biomarker model for predicting clinical progression in Alzheimer’s disease
Wang, X., Tang, Y., Zhang, Q., Xiang, B., Zeng, S., Zhang, Q., Gu, M., & Zou, L. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1728675
Reduced Plasma Aβ Peptides but Stable NfL and GFAP in Major Depressive Disorder
Fernández-Ceballos, M. D. L. Á., Vidal-Nogueira, L., Fernández-Pereira, C., Fortes-González, P., Salgado‐Barreira, Á., Ledo-Matos, E., Santana-Muriel, E., Baltanás, T. R., Olivares, J. M., Veiga, C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031474
Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease
Anand, T., & Kumar, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.002
Cui, L., Wang, Q.-M., Zhang, Z., Wang, M., Tu, Y.-Y., Jiang, J., Guan, Y., Li, Y.-H., Xie, F., & Guo, Q.-H. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100501
Hudák, A., Letoha, A., & Letoha, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031600
GFAP and the genetic code of astrocyte activation in Alzheimer’s disease
Upadhyay, R., Srinivasan, T. B., Umapriya, R., Chandrapragasam, V., & Sevanan, M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.007
Abraham, M. K., Indongo, G., Rajeevan, G., Arathy, B. K., Dhahir, D. M., & George, S. (2026) · ChemNanoMat · doi:10.1002/cnma.202500738
Özkurt, Ç., & Kelicen‐Uğur, P. (2026) · Biomarkers · doi:10.1080/1354750x.2026.2633568
Pham, H. B., Tống, M. T., Tran, N. T. L., Tran, T. T., Phan, T. H., Ching, C. T. S., Huynh, C. K., Ha, T.-T.-H., & Tran, C. T. (2026) · Microchimica Acta · doi:10.1007/s00604-026-07871-5
Plasma biomarkers of neurodegeneration across the spectrum of brain health
Cooper, J. G. (2026) · cIRcle (University of British Columbia)
Koenig, L. N., Huber, H., Chongtham, A., Molfetta, G. D., Andrews, R. D., Lukic, A., Shafiian, N., Fillit, H. M., Blennow, K., Ashton, N. J., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag074
Self-citationPriya, Mittal, R., Banerjee, J., & Dixit, A. B. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.006
Zhang, J.-W., Li, R., Niu, Y.-X., Liu, S., Li, C.-H., Hao, X., Wang, S., Chen, S., & Wang, F. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02016-5
Molinari, A. B., Silva, A. P. S., da Silva, A. B. C., de Sousa, J. V. G., Silva, T. B., & Valadares, B. L. B. (2026) · Brazilian Journal of Biological Sciences · doi:10.21472/bjbs.v13n28-024
Raajasekar, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9252110/v1
Gravandi, M. M., Komi, D. E. A., Amirian, R., Hosseini, S. Z., Alavi, S. D., Shirooie, S., Kiani, A., & Farzaei, M. H. (2026) · Journal of Food Biochemistry · doi:10.1155/jfbc/7471140
Plasma lipid trajectories improve prediction of future Alzheimer's disease
Zou, H., Wang, T., Huynh, K., Meikle, P. J., Kaddurah‐Daouk, R., Luo, S., & Initiative, T. F. L. D. N. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261435212
Abdullah, L. B., Zhang, F., Petersen, M. E., Hall, J., Handen, B. L., Mapstone, M. E., Christian, B. T., Head, E., Harley, S., Andrews, H., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71338
Linking neuroinflammation and neurodegeneration to cognitive decline in HIV
Ellis, R. J., Bao, Y., Chen, H., Letendre, S. L., Chenna, A., Yee, B., Winslow, J. W., Petropoulos, C. J., Farhadian, S., Mukerji, S. S., et al. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101241
Plasma proteomics of APOE genotype: age-specific analyses in UK population-based cohortsPreprint
Packer, A. E., Khatun, T., Groves, J. W., Wyss‐Coray, T., Schott, J. M., Proitsi, P., Anderson, E. L., & Williams, D. M. (2026) · medRxiv · doi:10.64898/2026.04.16.26351010
Poisnel, G., Lhérault, M., Palix, C., Turpin, A., Felisatti, F., Vrillon, A., Paquet, C., Chocat, A., Coulbault, L., Sayette, V. D. L., et al. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70248
Neri, L. (2026) · Florence Research (University of Florence)
Lee, H. B., Yoon, B., Hong, Y. J., Jeong, J. H., Kim, S., Wang, M. J., Choi, S. H., Ryu, J. S., Kang, S., Park, K. H., et al. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e184
Santos, L. T. R., Costa, F. L., Rosa, I. D., Frota, A. F., Bezerra, J. R., Soares, M. V. R., Barbosa, C. D. S. N., Farias, J. W. F., da Silva, L. R. A. M., Gonçalves, P. V. D. S., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261441581
Devi, C. S., Rao, D. S., & Kumar, S. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.19s.56
Hellgren, J., Strandberg, M., Hansson, O., Janelidze, S., Källén, K., & Svenningsson, A. (2026) · Acta Neurologica Scandinavica · doi:10.1155/ane/5453262
Self-citationGiordano, A., Mandrioli, J., Cerri, F., Lunetta, C., Saebfar, H., Catania, M., Battipaglia, C., Leone, L., Trojsi, F., Vizziello, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104208
Ma, X., Hansra, G. K., Jayasena, T., Crawford, J. D., Poljak, A., & Sachdev, P. S. (2026) · medRxiv · doi:10.64898/2026.05.14.26353162
2‐aminobutyrate mediates the impact of air pollution on blood biomarkers of Alzheimer's disease
Saeed, A., McKennan, C. G., Clougherty, J. E., Zhou, P., Tripathy, S., Kinnee, E., Duan, J., Kip, K. E., Zeng, X., Villemagne, V., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71388
Functional Pathological Features and Molecular Markers in Alzheimer’s Disease
Park, M.-N., Kim, H. W., Hong, J., Kim, J. K., Lee, S.-B., Baek, H. S., Kwak, S., Kwon, Y. J., Park, K., Jeon, J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114720
Redefining Alzheimer’s disease diagnostics in the age of blood-based biomarkers
Yadav, P. U., Baidya, A. T. K., & Kumar, R. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.006
The clinical utility of blood-based biomarkers of Alzheimer’s disease: Triumphs and pitfalls
Mir, M. M., Mir, G. M., Majid, A., Alharthi, M. H., & Alshahrani, A. M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.008
Zhu, N. (2026) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Xu, G.-W., Zhu, X.-L., & Yin, C.-H. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.121407
Investigating AD and non-AD [18F]flortaucipir distribution patterns in a memory clinic cohort
Piva, F., Boccalini, C., Ashton, N. J., Zetterberg, H., Blennow, K., Frisoni, G. B., Veronese, M., Garibotto, V., & Peretti, D. E. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07995-z
Self-citationTan, Z., Ping, J., Zhang, H., Zhang, Y., Kong, C., Lu, Y., Liu, B. A., Jiang, T., & Liu, X. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07730-1
Soni, H., Sutherland, G. T., & Hofer, M. J. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03927-8
Giacomucci, G., Pieri, A., Bagnoli, S., Giametta, K. M., Padiglioni, S., Moschini, V., Morinelli, C., Tabbì, S. M. R., Sensi, C., Mistretta, L., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13966-z
Karbownik, L., Kasterka, N., Kolasa, M., Figwer, A., Figwer, K., Dzitkowska, K., Czarny, N., Broniecka, A., Śmigielski, M., & Garbaciak, J. (2026) · Quality in Sport · doi:10.12775/qs.2026.59.72815
Pradhan, R., Anwar, M., Rao, A., Upadhyay, A. D., Gupta, A., Singh, A. K., Dey, A. B., & Dey, S. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71650
Sleep-related Alzheimer’s disease vulnerability in aging: A muscle-metabolic perspective
Coccurello, R. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106869
Lu, Y., Xu, C., Fu, P., & Gong, L. (2026) · Cells · doi:10.3390/cells15141284
Genetic architecture of Alzheimer’s disease-related plasma biomarkers
Aaltonen, A., Palviainen, T., Heikkinen, S., Herukka, S.-K., Hiltunen, M. O., Kokkola, T., Kärkkäinen, S., FinnGen, Palotie, A. V., Runz, H., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.07.010
Exploring longitudinal relationships among Alzheimer's disease biomarkers
Saef, B. A., Petersen, K. K., Volluz, K., Li, Y., Tosun, D., Milà‐Alomà, M., Shaw, L. M. J., Zetterberg, H., Dage, J. L., Rubel, C. E., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71711
Self-citationNovel Plasma Proteins Associated With Alzheimer’s Disease Risk in APOE ε4 Carriers and Non-carriersPreprint
Leng, Y., Ding, H., Yang, J., Liu, X., Lu, A., Tao, Q., Ma, J., Gifford, K. A., Ang, T. F. A., Qiu, W. Q., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10359931/v1
Smeriglio, E., Imbesi, M., Xiao, J., Smeriglio, A., & Trombetta, D. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1924338
Qi, X., Liu, R. M., Belsky, D. W., Tian, Q., Luo, H., Liu, Y., Xu, Z., Langa, K. M., & Wu, B. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71731
Abtahi, Y., Ghadiminia, N., Nasiri, H., Ladani, A. J., Khanghah, K. N., Shamspour, M., Jamaloei, D. D., Meybodi, F. S., Rahimi, S., Hashemi, D., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-66315-5
Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics
Vigneswaran, S., Verberk, I. M. W., Boonkamp, L., Veld, L. I. ‘., Simmelink, M. J. A., Antwi‐Berko, D., van Unen, L., Rousset, R. Z., Claessen, T., Zwan, M. D., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.28864
Self-citation
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.